logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pemetrexed (Alimta) for non-small cell lung cancer, advanced and/or metastatic – first line induction in combination with cisplatin, followed by maintenance therapy

< Back

Pemetrexed (Alimta) for non-small cell lung cancer, advanced and/or metastatic – first line induction in combination with cisplatin, followed by maintenance therapy

Drugs

Cancer and Palliative Care

September 2010


Pemetrexed disodium (Alimta, LY231514) is a multi-targeted inhibitor of three key enzymes in the folate metabolic pathway: thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. It leads to depletion of fully reduced folate, ultimately resulting in disruption to crucial metabolic processes essential for cell replication. Pemetrexed is administered by intravenous (IV) infusion at 500mg/m2 every 3 weeks in combination with IV cisplatin at 75mg/m2, vitamin supplementation, and dexamethasone during the induction phase (cycles 1-4); followed by a maintenance phase of IV pemetrexed 500mg/m2 every 3 weeks along with best supportive care, vitamin supplementation and dexamethasone until disease progression.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts